From: The impact of low-frequency, low-force cyclic stretching of human bronchi on airway responsiveness
 |  | Cyclic stretch effect on Δ (−log EC50), difference between control and stretch group | Effect of pretreatment | Effect size pretreatment | |
---|---|---|---|---|---|
n | in absence of pretreatment (log unit) | in presence of pretreatment (log unit) | (log unit) | |d| [95% CI] | |
Epithelium removal | 13 | 0.48 ± 0.08a | 0.50 ± 0.14b | 0.02 ± 0.13 | 0.05 [−0.70–0.80] |
Indomethacin (1 μM) | 8 | 0.38 ± 0.07a | 0.32 ± 0.13b | −0.05 ± 0.12 | −0.23 [−1.20–0.76] |
MK476 (1 μM) | 7 | 0.41 ± 0.07c | 0.26 ± 0.23 | −0.15 ± 0.24 | −0.34 [−1.37–0.74] |
L-NAME (1 mM) | 14 | 0.30 ± 0.07a | 0.44 ± 0.05a | 0.14 ± 0.05 | 0.54 [−0.23–1.28] |
Nicardipine (10 μM) | 10 | 0.57 ± 0.10a | 0.11 ± 0.12 | −0.45 ± 0.17d | −1.26 [−2.16– − 0.25] |
Tetrodotoxin (1 μM) | 7 | 0.25 ± 0.05c | 0.38 ± 0.04a | 0.13 ± 0.06 | 1.12 [−0.07–2.16] |
Gadolinium (0.1 mM) | 8 | 0.27 ± 0.05b | 0.49 ± 0.08a | 0.22 ± 0.08d | 1.19 [0.07–2.18] |
Tertiapine (10 μM) | 9 | 0.40 ± 0.13b | 0.41 ± 0.09c | 0.03 ± 0.19 | 0.03 [−0.90–0.95] |
Capsazepine (1 μM) | 8 | 0.40 ± 0.11c | 0.54 ± 0.12c | 0.14 ± 0.15 | 0.41 [−0.60–1.38] |
Calphostine C (0.1 μM) | 9 | 0.26 ± 0.04a | 0.24 ± 0.19 | −0.01 ± 0.20 | −0.04 [−0.80–0.88] |
SB203580 (0.1 μM) | 10 | 0.37 ± 0.07a | 0.36 ± 0.10 | −0.01 ± 0.13 | −0.04 [−0.91–0.84] |
Y27632 (1 μM) | 11 | 0.37 ± 0.08a | 0.37 ± 0.16b | −0.01 ± 0.16 | −0.12 [−0.95–0.72] |